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D
yspnoea is one of the commonest symptoms experienced by patients with cancer -
both as a feature of the disease and also as a consequence of its treatments.  In a
recent Canadian series of nearly 1000 cancer out-patients, 46% reported dyspnoea (1).
The Medical Research Council (MRC) of the UK has found that of lung cancer patients
entering its trials, dyspnoea was a presenting complaint in 87% of small cell cancer and in
86% of non-small cell cancer patients.  In advanced cancer, 33% of patients entering a
Japanese hospice reported dyspnoea but that rose to 66% near to death (2).
CAUSATION
Dyspnoea is the end result of many discrete but overlapping potential pathways of patho-
physiological change that can occur in patients with cancer.  These are modified and may
be amplified by :
- Co-morbidities (especially COPD, other chronic lung diseases and heart disease);
- De-conditioning associated with immobility and cancer cachexia;
- Effects of ageing;
In any single patient, several of these factors could be involved, to produce a symptom level
and an effect on functioning and quality of life.  Thus, the assessment and management of
dyspnoea requires a good understanding of the underlying mechanisms.  However, the clin-
ical features displayed by patients with dyspnoea are often non-specific and this often
makes it difficult -even with laboratory testing and medical imaging - to differentiate
between different pathophysiological causes.  
There are three basic dimensions of the sensation of dyspnoea: (1) Air hunger - the
unpleasant sensation of the need to breathe harder, but being unable to actually increase
ventilation; (2) Effort of breathing - the physical discomfort and tiredness associated with
prolonged hard breathing; (3) Chest tightness - the feeling of constriction in the chest wall
and the inability to breathe in or out.
There are several validated questionnaires, which have been developed to capture these
dimensions of dyspnoea and their impact on functioning and quality of life (3).
In broad terms, the main causes of dyspnoea are :
- Increased chemical or neurological drive to breathe
- Increased work of breathing
- Decreased neuromuscular power to ventilate.
Often in cancer patients, especially those with cachexia, there is a combination of these fac-
tors.  Identifying which of these mechanisms are at work in an individual patient can be
helpful for planning rational treatment.
The major neurochemical drives, which control normal breathing and can influence dysp-
noea, are the response to hypercapnia and to hypoxia.   Usually the hypercapnic drive is
stronger and is mainly responsible for the sensation of air hunger.  Hypercapnia results from
severe airflow obstruction or restrictive lung disease.  Hypoventilation can also arise from
restriction of chest movement by pleural effusion and ascites.  Very small increases in
PCO2 can give measurable change in the sensation of dyspnoea.
Hypoxia can be caused by loss of alveoli or small air-conducting bronchioles, leading to
reduced or turbulent airflow.  It can arise in bronchopneumonia, airflow obstruction, pul-
monary congestion and lung collapse.  Ventilation-perfusion mismatching, e.g., with pul-
monary thromboembolism, can also cause hypoxia.
Besides the neurochemical drives to respiration, the other important mechanisms that
impact on dyspnoea are the mechanoreceptors and the ergoreceptors (also called meta-
boreceptors) (4).  These are responsible for the increased ventilation seen in pulmonary
congestion (via J-receptors) and the generation of dyspnoea in muscle wasting conditions.
Increased work of breathing arises when the "ventilatory pump" is working against a signif-
icant strain, e.g., in pneumonia, pulmonary fibrosis, pleural effusion, lymphangitis carcino-
matosa, upper airway obstruction, and emphysema.  Clinical clues, which help to identify
this factor, include the patient favouring the upright position, or stridor.
Decreased neuromuscular power is seen in patients with neurological impairment, e.g.,
phrenic nerve palsy, cachexia and other wasting disorders (including steroid-induced
myopathy).  The maximal inspiratory pressure (MIP) is a useful pulmonary function labora-
tory method of determining neuromuscular power.
ASSESSMENT
Put together, the signals from the peripheral and medullary receptors to the brain process-
ing areas form the "feed-back" system, while the neurogenic flow from the brain to the res-
piratory muscles are the "feed-forward" system.  When an imbalance forms between thesetwo information flows, the resulting ’error signal’ is a key factor in the generation of the sen-
sation of dyspnoea4.
It is important to be aware of non-respiratory causes of dyspnoea, e.g., anaemia, heart fail-
ure and pulmonary thromboembolism.  With normal ageing, several changes take place -
- Decreased lung elasticity
- Decreased respiratory muscle strength
- Reduced forced vital capacity and peak flow rate
- Increased air-trapping
- Deterioration in gas exchange
- Reduced ventilatory response to hypoxia and hypercapnia
- Increased ventilatory response to exercise.
Bedside assessment of the breathless patient therefore requires several clinical measures:
- Observation of the patient’s position and behaviour
- Clinical examination of the chest and heart
- Pulse oximetry
- Simple exercise testing.
Further investigations that may be helpful include -
- Medical imaging (chest radiograph; ultrasound; CT for mediastinal features)
- Response in dynamic lung volumes to bronchodilator
- Flow-volume loop if upper airway obstruction is suspected
- MIP
MANAGEMENT
With the preceding grounding in respiratory physiology and understanding of the patholog-
ical mechanisms, it is possible to prepare a rational multimodal plan for management.  First,
treatable factors should be tackled, e.g., pleural effusion, heart failure, anaemia, and
reversible airflow obstruction.  If anti-cancer treatments are still feasible (radiation or
chemotherapy) then these should be started sooner rather than later.  
Agents, which modify the neurochemical drives, are most helpful for symptomatic pallia-
tion.  These include the opioids, benzodiazepines and oxygen.  Systematic review favours
oral or subcutaneous morphine but other opioids may have advantages (5).  The addition
of helium to oxygen (heliox) gives significant improvement to exercise-related dyspnoea in
lung cancer (6).   Novel approaches, e.g., nebulised frusemide, need further evaluation (7).
Non-pharmacological approaches are nearly always helpful, particularly in the early stages.
These include psychological therapies, breathing training and acupuncture (8).   However,
in the terminal stage, the management of dyspnoea requires sensitive use of sedation-
inducing drugs, oxygen and nursing care.
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